Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 12/23/21 → 8/21/25 |
Funding
- Delta Fly Pharma Incorporated: $60,897.00
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Pat
- Qasrawi, Ayman (PI)
- Hildebrandt, Gerhard (Former PI)